Biotechnology

A new study reveals Exicure's burixafor mobilizes stem cells in one hour, promising to streamline cancer treatment and unlock future gene therapies.

With major drug approvals on the horizon, Nuvalent's leadership will detail its strategy for its next-gen cancer therapies at an influential investor summit.

VectorY Therapeutics adds seasoned biotech architect Kevin Pojasek to its board, signaling a strategic push to accelerate its novel therapies for ALS and Alzheimer's.

Insulet launches its tubeless Omnipod 5 insulin pump and new Discover data platform in the Middle East, offering a new lifeline for a region in need.

A new partnership will integrate data from millions in India and the UAE, aiming to fix research bias and build more equitable AI-driven medicine.

Positive study results for Alvotech's Entyvio biosimilar could disrupt the IBD market, promising lower costs for a blockbuster chronic care treatment.

Everest Medicines bets big on MT1013, a novel dual-action drug poised to transform treatment for millions with chronic kidney disease complications.

Life sciences giant QIAGEN defies economic headwinds with strong 2025 results, signaling aggressive growth in single-cell analysis and bioinformatics.

iVeena promotes key execs as it prepares for clinical trials of a novel eye drop that could reshape pediatric myopia treatment worldwide.

A simple nasal spray could offer immediate, broad protection against the flu. New landmark studies show how this antibody-based shield could revolutionize prevention.

DuPont launches a new reverse osmosis element promising dairy processors up to 50% higher productivity without changing their existing systems or practices.

South Korean pharma giant Yuyu Pharma invests in James & Ella, the UK's top freeze-dried pet food brand, signaling a major push into the booming pet wellness market.

New preclinical data suggests Arcellx's CAR T therapy may offer a safer profile than rivals, potentially avoiding severe neurological side effects.

Amid financial scrutiny and following a major trial failure, Vistagen's upcoming Q3 update is a critical test for its novel pherine pipeline.

As GLP-1 drugs dominate, Veru Inc. advances a novel therapy to combat muscle loss, aiming for a new standard of 'quality' weight loss in older adults.

A world-first trial for personalized mRNA vaccines offers new hope for children with aggressive brain tumors, a mission born from a father's own fight.

MetaVia's drug vanoglipel gets a major boost from AI modeling, validating its potential to treat complex metabolic diseases like MASH and Type 2 Diabetes.

Caribou Biosciences unveils new data showing its 'off-the-shelf' CAR-T cells achieve deep, lasting responses in lymphoma and myeloma clinical trials.

Affinia Therapeutics gets the green light for a human trial of AFTX-201, a one-time therapy for a devastating genetic heart disease, BAG3 DCM.

With crucial data on its novel oral inflammation inhibitor looming, NodThera brings in seasoned leader Geoff McDonough to navigate the path to Phase 3.